Home * PLATFORMS * Preclinical Pharmacology

Preclinical Pharmacology

The preclinical pharmacology group provides support for drug discovery and drug development programs at ETC. The group develops establishes and validates in vitro and in vivo pharmacokinetic and metabolic methods to screen and evaluate small molecules and peptides for their drug-like properties.

The group also establishes in vivo disease models to validate potential drugable targets and to evaluate therapeutic properties of preclinical drug candidates.

In vitro ADME:
  • Metabolic stability tests using human, mouse, rat, dog and monkey liver microsomes
  • Cytochrome P-450 inhibition
  • Plasma stability test
  • Plasma protein binding test
  • Metabolite identification
In vivo Pharmacokinetics (PK):
  • Species - Mouse, Rat
  • Route of administration – intravenous and oral
PK - Bioanalysis:
  • Method development for small molecules and peptides
  • PK parameter analysis including absolute bioavailability
In vivo pharmacology:
  • Mouse xenograft models, e.g., colon cancer; gastric cancer; lymphoma; myeloma; prostate cancer, ovarian cancer
  • Mouse orthotopic models, e.g., leukaemia
Infectious disease
  • Renal infection
  • Liquid Chromatography coupled with Mass Spectrometer (Agilent 1200SL – Thermo Scientific TSQ Quantum Ultra mass spectrometer
  • Agilent 1290 Infinity LC - AB Sciex QTRAP 5500 mass spectrometer)